SWOG S1418 - A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Treatment for Triple-Negative Breast Cancer with >1 cm Residual Invasive Cancer or Positive Lymph Nodes After Neoadjuvant Therapy.
The purpose of this study is to compare the usual approach (i.e. no more treatment or additional post-operative chemotherapy), to any effects, good and/or bad, of the experimental drug MK-3475(also called pembrolizumab) after surgery. This study will allow researchers to know whether treatment with MK-3475 is better, the same, or worse than the usual approach.
Principal Investigator
William W. MacLaughlin, MD
Contact
Ora Mae Jackson, RN, OCN
757-534-5565
[email protected]
Locations
Peninsula Cancer Institute
12100 Warwick Blvd. Suite 201
Newport News, VA 23601
Peninsula Cancer Institute
120 King’s Way, Suite 3100
Williamsburg, VA 23185
Peninsula Cancer Institute
7544B Medical Drive
Gloucester, VA 23061
Cancer Specialists of Tidewater
1200 First Colonial Road, #204
Virginia Beach, VA 23454
Cancer Specialists of Tidewater
110-E Wimbledon Square
Chesapeake, VA 23320
Cancer Specialists of Tidewater
5839 Harbour View Blvd., #100
Suffolk, VA 23435
Status
Recruiting
Category
Oncology
Study #